Subtype
Endometrial Serous Adenocarcinoma
CI-CAN-00005168Explore in graph →
15 active trials2 evidence items
Loading cancer entity…
Subtype
CI-CAN-00005168Explore in graph →
Clinical trials
51 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 80 | Roswell Park Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05902988 |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer |
| recruiting |
| Phase 1 / Phase 2 |
| 200 |
| Volastra Therapeutics, Inc.INDUSTRY |
| 1 |
| Nov 4, 2025 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2026source: clinicaltrials